K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.29 CAD -0.19% Market Closed
Market Cap: 534.2m CAD
Have any thoughts about
Knight Therapeutics Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one GUD stock under the Base Case scenario is 5.5 CAD. Compared to the current market price of 5.29 CAD, Knight Therapeutics Inc is Undervalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GUD Relative Value
Base Case
5.5 CAD
Undervaluation 4%
Relative Value
Price
K
Worst Case
Base Case
Best Case

Valuation Multiples

1.5
P/S
P/S
Price to Sales
1.5
vs History
95
vs Industry
57
Median 3Y
1.8
Median 5Y
2.4
Industry
2.5
Forward
1.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-27.1
Median 5Y
-18.5
Industry
21.9
Forward
-874.4
More Details
10.1
P/OCF
P/OCF
Price to OCF
10.1
vs History
69
vs Industry
37
Median 3Y
15
Median 5Y
15
Industry
16.5
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
19
Median 3Y
16.1
Median 5Y
-3.2
Industry
23.6
More Details
0.7
P/B
P/B
Price to Book Value
0.7
vs History
85
vs Industry
68
Median 3Y
0.7
Median 5Y
0.8
Industry
2.1
More Details
1.1
EV/S
EV/S
Enterprise Value to Sales
1.1
vs History
95
vs Industry
64
Median 3Y
1.4
Median 5Y
1.7
Industry
2.6
Forward
1.1
More Details
2.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.4
vs History
98
vs Industry
62
Median 3Y
3
Median 5Y
3.5
Industry
5.2
More Details
7.7
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.7
vs History
77
vs Industry
38
Median 3Y
9.4
Median 5Y
9.7
Industry
13.3
Forward
6.8
More Details
302.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
302.5
vs History
3
vs Industry
3
Median 3Y
-34.6
Median 5Y
-28.8
Industry
16.6
Forward
11.9
More Details
7.6
EV/OCF
EV/OCF
Enterprise Value to OCF
7.6
vs History
71
vs Industry
42
Median 3Y
11.4
Median 5Y
11
Industry
15.6
More Details
19.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
19.3
vs History
36
vs Industry
31
Median 3Y
16.7
Median 5Y
8.8
Industry
19.1
More Details
0.6
EV/IC
EV/IC
Enterprise Value to IC
0.6
vs History
76
vs Industry
70
Median 3Y
0.6
Median 5Y
0.6
Industry
1.9
More Details

Multiples Across Competitors

GUD Competitors Multiples
Knight Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Knight Therapeutics Inc
TSX:GUD
534.2m CAD 1.5 -17.4 7.7 302.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
CA
K
Knight Therapeutics Inc
TSX:GUD
Average P/E: 32.4
Negative Multiple: -17.4 		N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Summary
GUD intrinsic value, competitors valuation, and company profile.
DCF Valuation
GUD stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GUD stock valuation using valuation multiples.
Wall Street Estimates
GUD price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GUD stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 201,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.